Oxford BioMedica is a leader in lentivirus based gene technology and ongoing manufacturing deals (CTL019 with Novartis) underpin the valuation. We expect pipeline focus in the near term as OXB aims to optimise development via out-licensing or externally funded SPVs. The newly announced strategy takes into account the balance of risk versus reward for stakeholders (against the backdrop of the significant financial resources required over the next two to three years to advance OXB’s value
06 Nov 2016
Balancing risk to optimise reward
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Balancing risk to optimise reward
- Published:
06 Nov 2016 -
Author:
Dr Susie Jana -
Pages:
15
Oxford BioMedica is a leader in lentivirus based gene technology and ongoing manufacturing deals (CTL019 with Novartis) underpin the valuation. We expect pipeline focus in the near term as OXB aims to optimise development via out-licensing or externally funded SPVs. The newly announced strategy takes into account the balance of risk versus reward for stakeholders (against the backdrop of the significant financial resources required over the next two to three years to advance OXB’s value